Burning Rock Biotech Ltd cash flow statement

In fiscal 2025, Burning Rock Biotech Ltd's operations generated −$4.0m of cash; it spent $730,383 on capital projects, leaving free cash flow of −$4.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Burning Rock Biotech Ltd: cash flow statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−23	−33	−11	−74	−68	−36	−13	−4
Depreciation and amortisation	4	5	5	7	18	19	7	3
Stock-based pay	1	3	25	44	49	37	22	2
Capital spending	4	6	9	32	9	1	1	1
Free cash flow	−26	−39	−19	−106	−77	−37	−14	−5
Free cash flow after stock pay	−27	−43	−45	−150	−126	−74	−35	−7
Share buybacks	0	1	0	0	—	—	—	—
Shares issued	—	—	0	—	—	—	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BNR vs CDXS BNR vs XGN BNR vs PSNL BNR vs HBIO

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Burning Rock Biotech Ltd's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Burning Rock Biotech Ltd.